Assessing the effects of teriparatide treatment on bone mineral density, bone microarchitecture, and bone strength

Journal of Bone and Joint Surgery

Volumn 96, Issue 11, 2014, Pages

  Kleerekoper, Michael ^a   Greenspan, Susan L ^b   Lewiecki, E Michael ^c   Miller, Paul D ^d   Kendler, David L ^e   Maricic, Michael ^f   Keaveny, Tony M ^g   Kopperdahl, David L ^h   Ruff, Valerie A ⁱ   Wan, Xiaohai ^j   Janos, Boris ⁱ   Krohn, Kelly ⁱ  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c NEW MEXICO CLINICAL RESEARCH AND OSTEOPOROSIS CENTER   (United States)

^d Health Sciences Center and Colorado Center for Bone Research   (United States)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f Catalina Pointe Rheumatology   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h ON Diagnostics   (United States)

ⁱ ELI LILLY AND COMPANY   (United States)

^j NOVARTIS PHARMA AG   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; COLLAGEN TYPE 1; CREATININE; PARATHYROID HORMONE[1-34]; PROCOLLAGEN; VITAMIN D; BONE DENSITY CONSERVATION AGENT;

ADULT; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; BLOOD SAMPLING; BONE BIOPSY; BONE DENSITY; BONE EROSION; BONE FRAGILITY; BONE MASS; BONE MINERAL; BONE REMODELING; BONE STRENGTH; BONE STRUCTURE; BONE TURNOVER; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; COMPRESSIVE STRENGTH; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORTICAL THICKNESS (BONE); CREATININE BLOOD LEVEL; DIARRHEA; DIZZINESS; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; ELBOW; FALLING; FEMALE; FEMUR NECK; FINITE ELEMENT ANALYSIS; FOLLOW UP; HIP; HUMAN; HYPERCALCEMIA; INSOMNIA; LUMBAR SPINE; MALAISE; MENOPAUSE; MUSCLE SPASM; NEURILEMOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; OSSIFICATION; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RADIUS; SPINE FRACTURE; THORAX PAIN; TRABECULAR BONE; VERTIGO; WEIGHT REDUCTION; WRIST; AGED; CANADA; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DRUG EFFECTS; MIDDLE AGED; MULTICENTER STUDY; PHASE 4 CLINICAL TRIAL; PHOTON ABSORPTIOMETRY; PROCEDURES; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY; X-RAY COMPUTED TOMOGRAPHY;

ABSORPTIOMETRY, PHOTON; AGED; AGED, 80 AND OVER; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CANADA; FEMALE; FINITE ELEMENT ANALYSIS; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; OSTEOPOROSIS; TERIPARATIDE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; UNITED STATES;

EID: 84902156995     PISSN: 00219355     EISSN: 15351386     Source Type: Journal    
DOI: 10.2106/JBJS.L.01757     Document Type: Article

References (33)

1. Marcus R, Majumder S. The nature of osteoporosis. In: Marcus R, Feldman D, Kelsey J, editors. Osteoporosis. 2nd ed. San Diego: Academic Press; 2001. p 3-17.
2. Parfitt AM. Implications of architecture for the pathogenesis and prevention of vertebral fracture. Bone. 1992;13(Suppl 2):S41-7.
3. Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res. 2003 Nov;18(11):1932-41. (Pubitemid 37377441)
4. Ma YL, Zeng Q, Donley DW, Ste-Marie LG, Gallagher JC, Dalsky GP, Marcus R, Eriksen EF. Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis. J Bone Miner Res. 2006 Jun;21(6):855-64. (Pubitemid 43787992)
5. Dempster DW, Zhou H, Recker RR, Brown JP, Bolognese MA, Recknor CP, Kendler DL, Lewiecki EM, Hanley DA, Rao DS, Miller PD, Woodson GC 3rd, Lindsay R, Binkley N, Wan X, Ruff VA, Janos B, Taylor KA. Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial. J Clin Endocrinol Metab. 2012 Aug;97(8):2799-808. Epub 2012 Jun 14.
6. Gomberg BR, Saha PK, Wehrli FW. Topology-based orientation analysis of trabecular bone networks. Med Phys. 2003 Feb;30(2):158-68. (Pubitemid 36222851)
7. Wehrli FW, Gomberg BR, Saha PK, Song HK, Hwang SN, Snyder PJ. Digital topological analysis of in vivo magnetic resonance microimages of trabecular bone reveals structural implications of osteoporosis. J Bone Miner Res. 2001 Aug;16(8):1520-31. (Pubitemid 32675204)
8. Crawford RP, Cann CE, Keaveny TM. Finite element models predict in vitro vertebral body compressive strength better than quantitative computed tomography. Bone. 2003 Oct;33(4):744-50. (Pubitemid 37222401)
9. Orwoll ES, Marshall LM, Nielson CM, Cummings SR, Lapidus J, Cauley JA, Ensrud K, Lane N, Hoffmann PR, Kopperdahl DL, Keaveny TM; Osteoporotic Fractures in Men Study Group. Finite element analysis of the proximal femur and hip fracture risk in older men. J Bone Miner Res. 2009 Mar;24(3):475-83.
10. Keaveny TM. Biomechanical computed tomography-noninvasive bone strength analysis using clinical computed tomography scans. Ann N Y Acad Sci. 2010 Mar;1192:57-65.
11. Kopperdahl DL, Hoffmann P, Sigurdsson S, Aspelund T, Siggeirsdottir K, Eiriksdottir G, Harris T, Gudnason VF, Keaveny TM. Enhancement of hip fracture prediction using finite element analysis of CT scans [Abstract]. J Bone Miner Res. 2010;25(Suppl S1):Z114. http://www.asbmr.org/Meetings/AnnualMeeting/ AbstractDetail.aspx?aid=918e83ed-ab2f-4503-adfb-e0cde8677656. Accessed 2014 Jan 22.
12. Amin S, Kopperdhal DL, Melton LJ 3rd, Achenbach SJ, Therneau TM, Riggs BL, Keaveny TM, Khosla S. Association of hip strength estimates by finite-element analysis with fractures in women and men. J Bone Miner Res. 2011 Jul;26(7):1593-600.
13. Keaveny TM, Donley DW, Hoffmann PF, Mitlak BH, Glass EV, San Martin JA. Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. J Bone Miner Res. 2007 Jan;22(1):149-57. (Pubitemid 46032608)
14. Keaveny TM, McClung MR, Wan X, Kopperdahl DL, Mitlak BH, Krohn K. Femoral strength in osteoporotic women treated with teriparatide or alendronate. Bone. 2012 Jan;50(1):165-70. Epub 2011 Oct 17.
15. Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, Shane E, Plavetić K, Müller R, Bilezikian J, Lindsay R. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res. 2001 Oct;16(10):1846-53. (Pubitemid 32911491)
16. Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster D, Cosman F. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet. 1997 Aug 23;350(9077):550-5. (Pubitemid 27348431)
17. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001 May 10;344(19):1434-41. (Pubitemid 32402100)
18. Reeve J, Meunier PJ, Parsons JA, Bernat M, Bijvoet OL, Courpron P, Edouard C, Klenerman L, Neer RM, Renier JC, Slovik D, Vismans FJ, Potts JT Jr. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. Br Med J. 1980 Jun 7;280(6228):1340-4. (Pubitemid 10124272)
19. Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman JM, Clancy AD, Gaich GA. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003 Jan;18(1):9-17. (Pubitemid 36008334)
20. Misof BM, Roschger P, Cosman F, Kurland ES, Tesch W, Messmer P, Dempster DW, Nieves J, Shane E, Fratzl P, Klaushofer K, Bilezikian J, Lindsay R. Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. J Clin Endocrinol Metab. 2003 Mar;88(3):1150-6. (Pubitemid 36337769)
21. Reeve J, Hesp R, Williams D, Hulme P, Klenerman L, Zanelli JM, Darby AJ, Tregear GW, Parsons JA. Anabolic effect of low doses of a fragment of human parathyroid hormone on the skeleton in postmenopausal osteoporosis. Lancet. 1976 May 15;1(7968):1035-8.
22. Greenspan SL, Perera S, Recker R, Wagner JM, Greeley P, Gomberg BR, Seaman P, Kleerekoper M. Changes in trabecular microarchitecture in postmenopausal women on bisphosphonate therapy. Bone. 2010 Apr;46(4):1006-10. Epub 2010 Jan 4.
23. Wehrli FW, Ladinsky GA, Jones C, Benito M, Magland J, Vasilic B, Popescu AM, Zemel B, Cucchiara AJ, Wright AC, Song HK, Saha PK, Peachey H, Snyder PJ. In vivo magnetic resonance detects rapid remodeling changes in the topology of the trabecular bone network after menopause and the protective effect of estradiol. J Bone Miner Res. 2008 May;23(5):730-40. (Pubitemid 351575027)
24. Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J; Committee of Scientific Advisors of the International Osteoporosis Foundation. The use of biochemical markers of bone turnover in osteoporosis. Osteoporos Int. 2000;11(Suppl 6):S2-17.
25. Gillings D, Koch G. The application of the principle of intention-to-treat to the analysis of clinical trials. Drug Inf J. 1991;25:411-24.
26. Benito M, Vasilic B, Wehrli FW, Bunker B, Wald M, Gomberg B, Wright AC, Zemel B, Cucchiara A, Snyder PJ. Effect of testosterone replacement on trabecular architecture in hypogonadal men. J Bone Miner Res. 2005 Oct;20(10):1785-91. Epub 2005 Jun 20.
27. McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, Omizo M, Donley DW, Dalsky GP, Eriksen EF. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med. 2005 Aug 8-22;165(15):1762-8. (Pubitemid 41138965)
28. FORTEO® (teriparatide [rDNA origin] injection) for subcutaneous use prescribing information. Eli Lilly and Company. 2012. http://pi.lilly.com/us/ forteo-pi.pdf. Accessed 2013 Sep 18.
29. Turner RT, Lotinun S, Hefferan TE, Morey-Holton E. Disuse in adult male rats attenuates the bone anabolic response to a therapeutic dose of parathyroid hormone. J Appl Physiol (1985). 2006 Sep;101(3):881-6. Epub 2006 May 4.
30. Cohen A, Boutroy S, Stein E, Liu X, Lappe J, Recker R, Dempster D, Zhou H, McMahon D, Zhang C, Young P, Zhou B, Wang J, Guo XE, Shane E. High resolution peripheral quantitative computed tomography (HRpQCT) detects improved trabecular volumetric BMD and microarchitecture in premenopausal women with idiopathic osteoporosis treated with teriparatide. J Bone Miner Res 2011;26(Suppl 1). http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail. aspx?aid=6a58a567-7a2b-4b2c-8663-1aea3e53dd86. Accessed 2012 Oct 29.
31. Keaveny TM, Hoffmann PF, Singh M, Palermo L, Bilezikian JP, Greenspan SL, Black DM. Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans. J Bone Miner Res. 2008 Dec;23(12):1974-82.
32. Wang X, Sanyal A, Cawthon PM, Palermo L, Jekir M, Christensen J, Ensrud KE, Cummings SR, Orwoll E, Black DM, Keaveny TM; Osteoporotic Fractures in Men (MrOS) Research Group. Prediction of new clinical vertebral fractures in elderly men using finite element analysis of CT scans. J Bone Miner Res. 2012 Apr;27(4):808-16.
33. Gomberg BR, Wehrli FW, Vasilić B, Weening RH, Saha PK, Song HK, Wright AC. Reproducibility and error sources of micro-MRI-based trabecular bone structural parameters of the distal radius and tibia. Bone. 2004 Jul;35(1):266-76. (Pubitemid 38789174)